You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 13, 2024

Investigational Drug Information for Milademetan


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Milademetan?

Milademetan is an investigational drug.

There have been 12 clinical trials for Milademetan. The most recent clinical trial was a Phase 1 trial, which was initiated on July 14th 2021.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Leukemia. The leading clinical trial sponsors are Daiichi Sankyo, Inc., Rain Oncology Inc, and Rain Therapeutics Inc.

There are ten US patents protecting this investigational drug and sixty-four international patents.

Recent Clinical Trials for Milademetan
TitleSponsorPhase
Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast CancerRain Oncology IncPhase 2
Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast CancerInstitut CuriePhase 2
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A LossRain Oncology IncPhase 1/Phase 2

See all Milademetan clinical trials

Clinical Trial Summary for Milademetan

Top disease conditions for Milademetan
Top clinical trial sponsors for Milademetan

See all Milademetan clinical trials

US Patents for Milademetan

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Milademetan ⤷  Sign Up Crystals of dispiropyrrolidine derivatives Daiichi Sankyo Company, Limited (Tokyo, JP) ⤷  Sign Up
Milademetan ⤷  Sign Up Crystals of dispiropyrrolidine derivatives Daiichi Sankyo Company, Limited (Tokyo, JP) ⤷  Sign Up
Milademetan ⤷  Sign Up Method for treating cancer by combined use DAIICHI SANKYO COMPANY, LIMITED (Tokyo, JP) ⤷  Sign Up
Milademetan ⤷  Sign Up Dispiropyrrolidine derivatives Daiichi Sankyo Company, Limited (Tokyo, JP) ⤷  Sign Up
Milademetan ⤷  Sign Up Crystals of dispiropyrrolidine derivatives Daiichi Sankyo Company, Limited (Tokyo, JP) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Milademetan

Drugname Country Document Number Estimated Expiration Related US Patent
Milademetan Brazil BR112015004816 2032-09-06 ⤷  Sign Up
Milademetan Canada CA2884238 2032-09-06 ⤷  Sign Up
Milademetan China CN104812757 2032-09-06 ⤷  Sign Up
Milademetan European Patent Office EP2894156 2032-09-06 ⤷  Sign Up
Milademetan Spain ES2637150 2032-09-06 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.